저 AFP 간세포암 환자에서 혈중 sICAM-1의 간세포암 표지자로서의 의의 (Serum Concentration of Intercellular Adhesion Molecule-1 (ICAM-1) in Patients with Hepatocellular Carcinoma (HCC) with Low AFP ) |
|
|
Serum Concentration of Intercellular Adhesion Molecule-1 (ICAM-1) in Patients with Hepatocellular Carcinoma (HCC) with Low AFP |
Hyun Ju Park, Joung Il Lee, Seok Ho Dong, Hyo Jong Kim, Byoung Ho Kim, Young Woon Chang and Rin Chang |
Department of Internal Medicine, KyungHee University School of Medicine |
|
|
ABSTRACT |
|
Background/Aims : In HCC with low AFP. we have to use repeated imaging study to evaluate residual viable rumor or recurrence after TACE ( transarterial chemoembolization). We performed the study to know that sICAM- 1 in HCC can be a tumor marker of diagnosis and has cor relation with tumor size or clinical staging. The results were compared with PIVKA- , an another tumor marker of HCC. Met hods : Previously untreat ed 39 pat ients with HCC were evaluated. Serum sICAM- 1, AFP and PIVKA- II were measured by EIA, immunoradiometric assay and EIA, respectively. Tumor size were meas ured by abdominal CT and angiogr aphy. Results : Range of sICAM- 1 levels with HCC patients were 189.0 to 983.6 ng/ mL, and mean value was 668.3+- 254.4 ng/ mL. Thirty four of the 39 patients (87.2%) with HCC showed sICAM- 1 levels higher than 306.4 ng/ mL (mean of 131 healt hy controls + 2SD level). Range of PIVKA-Ⅱ level with HCC patients were 25.3 to 2,779.3mAU/nL, and mean value was 1,340.1+-1,091.1mAU/mL. seven of the 39 patients(94.9%) with HCC showde PIVKA-Ⅱlevels higher than 40mAU/mL. Range of AFP levels with HCC patients were 4.2 to 57,520ng/mL, and mean value was 4,215.6+-10,807.2ng/mL. 10 patients (26%) showed AFP lower than 20ng/mL, and 17 patients(44%) were AFP lower than 100ng/mL. All of the 17 patients with αFP lower than 100ng/mL had s ICAM- 1 levels more than reference range (mean of 131 healt hy cont r ols + 2 SD level), and PIVKA- II levels also more than reference range. Positive correlation was observed between PIVKA- II level and tumor size in 18 patients without vascular invasion. Accor ding t o HCC clinical staging, 10 patients (25.6%) belonged clinical stage Ⅱ. 5 pat ients (12.8%) Ⅲ, 24 pat ients ( 61.5%) Ⅳ. Both of PIVKA- II and sICAM- 1 levels of stage showed significantly higher than stage Ⅱ. PIVKA-Ⅱ showed more positive correlation with tumor size and clinical stage than sICAM- 1. No correlation was found between AFP and sICAM- 1, and positive correlation was AFP and PIVKA- II. Conclusion: In HCC patients with low AFP, sICAM- 1 and PIVKA- II correlated with tumor size and clinical stage. sICAM- 1 and PIVKA- II may be a useful marker of diagnosis . So, we need to further study to evaluate whether sICAM- 1 and PIVKA- II can be used as a marker of disease progression or prognosis . (Korean J Hepatol 1998;4:346 357) |
KeyWords:
Hepatocellular carcinoma (HCC), AFP, sICAM-1, PIVKA-II |
|
|